List view / Grid view
Here, we present IDBS Polar, a platform that securely manages drug progression in contexts of workflow, integration and insight.
A report has been backed by eight industry leaders who say that updating R&D tax credit systems in the UK would release £4 billon of growth every year.
Researchers in Boston have repurposed their lab into a centre to test samples for COVID-19, releasing a blueprint of how to do so for other labs in the US.
Last year, the European Patent Office (EPO) saw the number of patents filed in the pharmaceutical and biotechnology sectors rise for the third year in a row.
The ABPI has outlined how the new immigration system in the UK will affect life science workers and businesses, emphasising the need for regular reviews to remain competitive.
Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been broadly rejected by the European Patents Office.
Boris Johnson, the Prime Minister of the UK, has announced a new Global Talent visa for researchers and scientists which will fast track those in certain fields.
The Cubis® II balance, with pharma package, contains all the technical controls to support compliance with common regulations.
The International Society for Cell and Gene Therapy has created a group to tackle the rising number of commercial cell bank services that are misleading patients.
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
ZYNTEGLO™ is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT).
The court held that the defendants adulterated and misbranded a stem cell drug product made from a patient’s adipose tissue.
Arizona company claims their products can treat Lyme disease, diabetes, Parkinson’s disease and more, but have not been approved for any use.
The General Data Protection Regulation (GDPR) is a new set of EU rules governing how a company manages, protects and administers personal data. Whether you are a subscriber, author, advertiser or supplier to our journal, we may hold information about you and we need to keep it private and secure.
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
